ANL 31.50 Decreased By ▼ -0.29 (-0.91%)
ASC 18.90 Decreased By ▼ -0.83 (-4.21%)
ASL 26.27 Decreased By ▼ -0.13 (-0.49%)
AVN 91.95 Decreased By ▼ -0.05 (-0.05%)
BOP 8.30 Decreased By ▼ -0.06 (-0.72%)
BYCO 12.85 Increased By ▲ 0.06 (0.47%)
DGKC 127.20 Increased By ▲ 0.10 (0.08%)
EPCL 47.90 Decreased By ▼ -0.86 (-1.76%)
FCCL 24.18 Increased By ▲ 0.12 (0.5%)
FFBL 26.55 Increased By ▲ 0.25 (0.95%)
FFL 17.80 No Change ▼ 0.00 (0%)
HASCOL 11.32 Decreased By ▼ -1.01 (-8.19%)
HUBC 80.25 Decreased By ▼ -0.75 (-0.93%)
HUMNL 9.12 Increased By ▲ 0.36 (4.11%)
JSCL 23.40 Decreased By ▼ -0.93 (-3.82%)
KAPCO 43.07 Decreased By ▼ -0.18 (-0.42%)
KEL 4.30 Decreased By ▼ -0.21 (-4.66%)
LOTCHEM 15.99 Increased By ▲ 0.19 (1.2%)
MLCF 48.75 Increased By ▲ 0.10 (0.21%)
PAEL 35.40 Decreased By ▼ -0.40 (-1.12%)
PIBTL 11.96 Increased By ▲ 0.75 (6.69%)
POWER 10.20 Decreased By ▼ -0.16 (-1.54%)
PPL 90.49 Decreased By ▼ -0.66 (-0.72%)
PRL 26.15 Increased By ▲ 0.50 (1.95%)
PTC 13.00 Decreased By ▼ -0.01 (-0.08%)
SILK 1.84 Increased By ▲ 0.18 (10.84%)
SNGP 47.58 Decreased By ▼ -0.77 (-1.59%)
TRG 164.60 Decreased By ▼ -0.90 (-0.54%)
UNITY 44.75 Decreased By ▼ -2.35 (-4.99%)
WTL 4.14 Increased By ▲ 0.22 (5.61%)
BR100 5,278 Decreased By ▼ -22.7 (-0.43%)
BR30 27,522 Decreased By ▼ -167.85 (-0.61%)
KSE100 48,239 Decreased By ▼ -195.99 (-0.4%)
KSE30 19,426 Decreased By ▼ -94.82 (-0.49%)

University of Oxford

Oxford-developed Malaria vaccine hailed as potential medical breakthrough
World

Oxford-developed Malaria vaccine hailed as potential medical breakthrough

  • A malaria vaccine, developed by the University of Oxford, has proved to be 77% effective in early trials; being seen as a potential major breakthrough in the fight against the disease.
  • On the basis of these results, larger trials will now be carried out in nearly 5000 children between the ages of five months and three years, across four African states.
Published 23 Apr, 2021 04:03pm
Oxford study indicates AstraZeneca effective against Brazil variant
World

Oxford study indicates AstraZeneca effective against Brazil variant

  • The source did not provide the exact efficacy of the vaccine against the variant. They said the full results of the study should be released soon, possibly in March.
  • The information comes as a small-sample study suggested the COVID-19 vaccine developed by China's Sinovac may not work effectively against the Brazilian variant.
Published 05 Mar, 2021 09:00pm